The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 03, 2021

Filed:

Feb. 08, 2018
Applicants:

Novartis Ag, Basel, CH;

Palobiofarma S.l., Mataro Barcelona, ES;

Inventors:

Sanela Bilic, Urbandale, IA (US);

Juan Alberto Camacho Gomez, Mataro Barcelona, ES;

John Scott Cameron, Belmont, MA (US);

Julio Cesar Castro-Palomino Laria, Matero Barcelona, ES;

Danny Roland Howard, Jr., Washington, NJ (US);

Assignees:

Novartis AG, Basel, CH;

Palobiofarma S.L., Barcelona, ES;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 403/14 (2006.01); C07K 16/28 (2006.01); A61K 31/506 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C07D 403/14 (2013.01); A61K 31/506 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 2317/565 (2013.01);
Abstract

This invention relates to an active metabolite of 5-bromo-2,6-di(1H-pyrazol-1-yl)pyrimindin-4-amine that modulates the activity of adenosine A2a receptor. In particular, the present invention relates to pharmaceutical compositions comprising 1-(4-amino-5-bromo-6-(1H-pyrazol-1-yl)-pyrimidin-2-yl)-1H-pyrazol-4-ol, as well as processes for its preparation and its use in the treatment of cancer alone of in combination with one or more immunotherapeutic agents.


Find Patent Forward Citations

Loading…